Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
Request for Extension of Time to File a Statement of Use
(15 U.S.C. Section 1051(d))
The table below presents the data as entered.
Input Field
|
Entered
|
SERIAL NUMBER |
87168201 |
LAW OFFICE ASSIGNED |
LAW OFFICE 110 |
MARK SECTION |
MARK |
NEXCELUS (see, http://uspto.report/TM/87168201/mark.png) |
STANDARD CHARACTERS |
YES |
USPTO-GENERATED IMAGE |
YES |
LITERAL ELEMENT |
NEXCELUS |
OWNER SECTION (current) |
NAME |
Bellicum Pharmaceuticals, Inc. |
STREET |
2130 W. Holcombe Drive, Suite 800 |
CITY |
Houston |
STATE |
Texas |
ZIP/POSTAL CODE |
77030 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
OWNER SECTION (proposed) |
NAME |
Bellicum Pharmaceuticals, Inc. |
STREET |
2130 W. Holcombe Drive, Suite 800 |
CITY |
Houston |
STATE |
Texas |
ZIP/POSTAL CODE |
77030 |
STATE/COUNTRY/REGION/JURISDICTION/U.S. TERRITORY |
United States |
EMAIL |
XXXX |
CORRESPONDENCE INFORMATION (current) |
NAME |
JOHN PAUL OLEKSIUK |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
trademarks@cooley.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
jpo@cooley.com; cghazarian@cooley.com; dkoons@cooley.com |
CORRESPONDENCE INFORMATION (proposed) |
NAME |
John Paul Oleksiuk |
PRIMARY EMAIL ADDRESS FOR CORRESPONDENCE |
trademarks@cooley.com |
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES) |
jpo@cooley.com; cghazarian@cooley.com; dkoons@cooley.com |
DOCKET/REFERENCE NUMBER |
306803-20000 |
GOODS AND/OR SERVICES SECTION |
INTERNATIONAL CLASS |
005 |
CURRENT IDENTIFICATION |
Pharmaceutical preparations for use in connection with cellular transplants |
GOODS OR SERVICES |
KEEP ALL LISTED |
EXTENSION SECTION |
EXTENSION NUMBER |
5 |
ONGOING EFFORT |
product or service research or development |
ALLOWANCE MAIL DATE |
09/26/2017 |
STATEMENT OF USE |
NO |
PAYMENT SECTION |
NUMBER OF CLASSES |
1 |
SUBTOTAL AMOUNT [EXTENSION FEE] |
125 |
TOTAL AMOUNT |
125 |
SIGNATURE SECTION |
SIGNATURE |
/Atabak Mokari/ |
SIGNATORY'S NAME |
Mokari, Atabak |
SIGNATORY'S POSITION |
CFO |
DATE SIGNED |
03/04/2020 |
SIGNATORY'S PHONE NUMBER |
N/A |
FILING INFORMATION |
SUBMIT DATE |
Mon Mar 09 12:00:09 ET 2020 |
TEAS STAMP |
USPTO/ESU-XXX.XXX.XXX.XX-
20200309120009757566-8716
8201-710126d9de89b3915ca1
f61d55f048b112613017c8d31
1f98242f9c847879da7-DA-00
098479-202003021909567645
87 |
Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number.
PTO Form 1581 (Rev 09/2005) |
OMB No. 0651-0054 (Exp 12/31/2020) |
SOU Extension Request
(15 U.S.C. Section 1051(d))
To the Commissioner for Trademarks:
MARK: NEXCELUS (see, http://uspto.report/TM/87168201/mark.png)
SERIAL NUMBER: 87168201
OWNER AND/OR ENTITY INFORMATION
The owner proposes to amend the following:
Current: Bellicum Pharmaceuticals, Inc., having an address of
2130 W. Holcombe Drive, Suite 800
Houston, Texas 77030
United States
Proposed: Bellicum Pharmaceuticals, Inc., having an address of BB
2130 W. Holcombe Drive, Suite 800
Houston, Texas 77030
United States
Phone:
Fax:
Email: XXXX
The owner requests a six-month extension of time to file the Statement of Use under 37 C.F.R. Section 2.89 in this application. The Notice of Allowance mailing date was 09/26/2017.
For International Class 005:
Current identification: Pharmaceutical preparations for use in connection with cellular transplants
For a trademark/service mark: The applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all of the goods/services listed in the Notice
of Allowance or as subsequently modified for this specific class; for a collective/certification mark: the applicant has a continued bona fide intention, and is entitled, to exercise legitimate
control over the use of the mark in commerce on or in connection with the goods/services/collective membership organization listed in the Notice of Allowance, or as subsequently modified for this
specific class.
This is the fifth extension request. The applicant has made the following ongoing efforts to use the mark in commerce on or in connection with each of those goods/services covered by the extension
request: product or service research or development
Correspondence Information (current):
JOHN PAUL OLEKSIUK
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): jpo@cooley.com; cghazarian@cooley.com; dkoons@cooley.com
Correspondence Information (proposed):
John Paul Oleksiuk
PRIMARY EMAIL FOR CORRESPONDENCE: trademarks@cooley.com
SECONDARY EMAIL ADDRESS(ES) (COURTESY COPIES): jpo@cooley.com; cghazarian@cooley.com; dkoons@cooley.com
Requirement for Email and Electronic Filing: I understand that a valid email address must be maintained by the owner/holder and the owner's/holder's attorney, if appointed, and that all
official trademark correspondence must be submitted via the Trademark Electronic Application System (TEAS).
A fee payment in the amount of $125 will be submitted with the form, representing payment for 1 class.
Declaration
STATEMENTS: The signatory believes that: the applicant has a continued bona fide intention, and is entitled, to use the mark in commerce on or in connection with all the goods/services under Section
1(b) in the notice of allowance or as subsequently modified, or, if applicable, the applicant has a continued bona fide intention, and is entitled, to exercise legitimate control over the use of the
mark in commerce on or in connection with all the goods/services/collective membership organization under Section 1(b) in the notice of allowance or as subsequently modified; and that to the best of
the signatory's knowledge and belief, no other persons, except, if applicable, members and concurrent users, have the right to use the mark in commerce, either in the identical form or in such near
resemblance as to be likely, when used on or in connection with the goods/services/collective membership organization of such other persons, to cause confusion or mistake, or to deceive.
DECLARATION: The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001, and that such willful false statements and
the like may jeopardize the validity of the application or submission or any resulting registration, declares that all statements made of his/her own knowledge are true and that all statements made
on information and belief are believed to be true.
Signature: /Atabak Mokari/ Date Signed: 03/04/2020
Signatory's Name: Mokari, Atabak
Signatory's Position: CFO
Signatory's Phone: N/A
RAM Sale Number: 87168201
RAM Accounting Date: 03/09/2020
Serial Number: 87168201
Internet Transmission Date: Mon Mar 09 12:00:09 ET 2020
TEAS Stamp: USPTO/ESU-XXX.XXX.XXX.XX-202003091200097
57566-87168201-710126d9de89b3915ca1f61d5
5f048b112613017c8d311f98242f9c847879da7-
DA-00098479-20200302190956764587